Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Adenocarcinoma, Bronchiolo-Alveolar 7Adenocarcinoma of Lung 6Lung Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Colonic Neoplasms 4Head and Neck Neoplasms 3Colorectal Neoplasms 3Skin Neoplasms 2Ovarian Neoplasms 2Gliosarcoma 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Untreated Childhood Anaplastic Astrocytoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Unspecified Adult Solid Tumor, Protocol Specific 1Tongue Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Solitary Fibrous Tumor, Pleural 1Salivary Gland Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Parathyroid Neoplasms 1Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter 1

Interventions

Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Recurrent Uterine Corpus Carcinoma × Gefitinib × Clear all
NCT00027690 2019-07-23

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡